Market research
IMMX Immix Biopharma Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 868M
- P/E ratio
- Not available
- Analyst target
- 21.15
- Dividend yield
- Not available
- Beta
- 0.2
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US45258H1068
- Market cap
- 868M
- P/E ratio
- Not available
- Analyst target
- 21.15
- Dividend yield
- Not available
- Beta
- 0.2
About
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the IMMX discussion.
No comments yet
Start a focused discussion about IMMX.